References
1. O’Sullivan JB, Mahan CM. Mortality related to diabetes and blood glucose levels in a community study. Am J Epidemiol. 1982 Oct;116(4):678-84.
2. Asadollahi K, Beeching N, Gill G. Hyperglycaemia and mortality. J R Soc Med. 2007 Nov;100(11):503-7.
3. Palumbo F, Bianchi C, Miccoli R, Del PS. Hyperglycaemia and cardiovascular risk. Acta Diabetol. 2003 Dec;40(Suppl 2):S362-9.
4. DeGroot J. The AGE of the matrix: chemistry, consequence and cure. Curr Opin Pharmacol. 2004 Jun;4(3):301-5.
5. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/003640.htm. Accessed January 16, 2008.
6. Dailey G. Assessing glycemic control with self-monitoring of blood glucose and hemoglobin A(1c) measurements. Mayo Clin Proc. 2007 Feb;82(2):229-35.
7. Osterman-Golkar SM, Vesper HW. Assessment of the relationship between glucose and A1c using kinetic modeling. J Diabetes Complications. 2006 Sep;20(5):285-94.
8. Robert L, Robert AM, Fulop T. Rapid increase in human life expectancy: will it soon be limited by the aging of elastin? Biogerontology. 2008;Jan 4.
9. Vasdev S, Gill V, Singal P. Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications. Cell Biochem Biophys. 2007;49(1):48-63.
10. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. Curr Neurol Neurosci Rep. 2007 Sep;7(5):373-80.
11. Yamagishi S, Adachi H, Takeuchi M, et al. Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm Metab Res. 2007 Nov;39(11):845-8.
12. Nawale RB, Mourya VK, Bhise SB. Non-enzymatic glycation of proteins: a cause for complications in diabetes. Indian J Biochem Biophys. 2006 Dec;43(6):337-44.
13. Landgraf R. HbA1c—the gold standard in the assessment of diabetes treatment? Dtsch Med Wochenschr. 2006 Dec;131(Suppl 8):S243-6.
14. Takeuchi M, Yamagishi S. TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses. 2004;63(3):449-52.
15. Available at: http://labtestsonline.org/understanding/analytes/a1c/test.html. Accessed January 18, 2008.
16. Hudson PR, Child DF, Jones H, Williams CP. Differences in rates of glycation (glycation index) may significantly affect individual HbA1c results in type 1 diabetes. Ann Clin Biochem. 1999 Jul;36(Pt 4):451-9.
17. Geberhiwot T, Haddon A, Labib M. HbA1c predicts the likelihood of having impaired glucose tolerance in high-risk patients with normal fasting plasma glucose. Ann Clin Biochem. 2005 May;42(Pt 3):193-5.
18. Harper JM, Durkee SJ, Smith-Wheelock M, Miller RA. Hyperglycemia, impaired glucose tolerance and elevated glycated hemoglobin levels in a long-lived mouse stock. Exp Gerontol. 2005 Apr;40(4):303-14.
19. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007 May;30(5):1049-55.
20. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003 Jan;26 Suppl 1:S33-50.
21. Baron P. The ten most important blood tests. Life Extension. 2006 May;12(5):42-51.
22. Yudkin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ. Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia. 1990 Apr;33(4):208-15.